Pharsight

Verkazia patents expiration

Can you believe VERKAZIA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220694 HARROW EYE Emulsion compositions containing cetalkonium chloride
Jan, 2026

(1 year, 7 months from now)

US7973081 HARROW EYE Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(1 year, 7 months from now)

US8524779 HARROW EYE Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(1 year, 7 months from now)

US11612658 HARROW EYE Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same
Jan, 2026

(1 year, 7 months from now)

US9956289 HARROW EYE Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(1 year, 7 months from now)

US8298568 HARROW EYE Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
Nov, 2027

(3 years from now)

US9132071 HARROW EYE Compositions containing quaternary ammonium compounds
Jun, 2029

(4 years from now)

Verkazia is owned by Harrow Eye.

Verkazia contains Cyclosporine.

Verkazia has a total of 7 drug patents out of which 0 drug patents have expired.

Verkazia was authorised for market use on 23 June, 2021.

Verkazia is available in emulsion;ophthalmic dosage forms.

Verkazia can be used as for the treatment of vernal keratoconjunctivitis in children and adults.

The generics of Verkazia are possible to be released after 02 June, 2029.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-358) Jun 23, 2028
New Product(NP) Jun 23, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 June, 2021

Treatment: For the treatment of vernal keratoconjunctivitis in children and adults

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage

VERKAZIA family patents

Family Patents